HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

High bleeding risk: is BMS still justifiable?

Original Title: Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?...

Diabetes has higher impact on DES outcomes than disease complexity

Original Title: Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary...

SORT OUT IV at 5 years: second generation DES efficacy confirmed

Original Title: Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-Year results from SORT OUT IV. Reference: Jensen LO...

In saphenous vein graft lesions, 1st and 2nd generation DES have similar outcomes

Long-Term Outcomes with First vs. Second-Generation Drug-Eluting Stents in Saphenous Vein Graft Lesions. Nagendra R. Pokala. Catheterization...

Definite/Probable Thrombosis with Bioresorbable Scaffolds

Original Title: Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold. A Systematic Review and...

Polymer-Free Biolimus Coated Stent: 5 Year Outcomes

Original Title: Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions4- and 12-Month Angiographic...

Dual Antiplatelet Therapy after Everolimus Eluting Stenting

Original Title: Benefits and Risks of Extended Dual Antiplatelet Therapy after Everolimus-Eluting Stents. For the Dual Antiplatelet Therapy...

ADAPT-DES: Proton Pump Inhibitors and Clopidogrel in Patients with DES

Original Title: Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients. The...